A flurry of recent studies has implicated KIF18A as a tractable therapeutic vulnerability specifically in cancers with aneuploidy, CIN, weakened APC/C activity, and SAC persistence [142,143,144,145,146]. Here, KIF18A is linked to cervical squamous intraepithelial neoplasia.